Evolved resistance to one antibiotic may be associated with "collateral" sensitivity to other drugs. Here we provide an extensive quantitative characterization of collateral effects in Enterococcus faecalis, a gram-positive opportunistic pathogen.
INTRODUCTION
The rapid emergence of drug resistance is an urgent threat to effective treatments for bacterial infections, cancers and many viral infections (1, 2, 3, 4, 5, 6) . Unfortunately, the development of novel drugs is a long and arduous process, underscoring the need for alternative approaches to forestall resistance evolution. Recent work has highlighted the promise of evolution-based strategies for optimizing and prolonging the efficacy of established drugs, including optimal dose scheduling (7, 8, 9) , antimicrobial stewardship (10, 11) , drug cycling (12, 13, 14) , consideration of spatial dynamics (15, 16, 17) , cooperative dynamics (18, 19, 20, 21) , or phenotypic resistance (22, 23, 24) , and judicious use of drug combinations (25, 26, 27, 28, 29, 30, 31, 32) . In a similar spirit, a number of recent studies have suggested exploiting collateral sensitivity as a means for slowing or even reversing antibiotic resistance (33, 34, 35, 36, 37, 38) .
Collateral evolution occurs when a population evolves resistance to a target drug while simultaneously exhibiting increased sensitivity or resistance to a different drug.
From an evolutionary perspective, collateral effects are reminiscent of the trade-offs inherent when organisms are required to simultaneously adapt to different tasks, an optimization that is often surprisingly simple because it takes place on a lowdimensional phenotypic space (39, 40) . If similarly tractable dynamics occur in the evolution of multi-drug resistance, systematic optimization of drug deployment has the promise to mitigate the effects of resistance.
Indeed, recent studies in bacteria have shown that the sequential (41, 42, 43, 44, 45, 38, 46) or simultaneous (47, 48) deployment of antibiotics with mutual collateral sensitivity can sometimes slow the emergence of resistance. Unfortunately, collateral profiles have also been shown to be highly heterogeneous (49, 50) and often not repeatable (51) , potentially complicating the design of successful collateral sensitivity cycles. The picture that emerges is enticing, but complex; while collateral effects offer a promising new dimension for improving therapies, the design of drug cycling protocols is an extremely difficult problem that requires optimization at multiple scales, from dynamics within individual hosts to those that occur at the hospital or community scale.
Despite many promising recent advances, it is not yet clear how to optimally harness collateral evolutionary effects to design drug policies, even in simplified laboratory scenarios. The problem is challenging for many reasons, including the stochastic nature of evolutionary trajectories and-at an empirical level-the relative paucity of data regarding the prevalence and repeatability of collateral sensitivity profiles in different species.
In this work, we take a step towards answering these questions by investigating how drug sequences might be used to slow resistance in a simplified, single-species bacterial population. We show that even in this idealized scenario, intuitive cycling protocols-for example, sequential application of two drugs exhibiting reciprocal collateral sensitivity-are expected to fail over long time periods, though mathematically optimized policies can maintain long-term drug sensitivity at the price of transient periods of high resistance. As a model system, we focus on Enterococcus faecalis, a gram-positive opportunistic bacterial pathogen. E. faecalis are found in the gastrointestinal tracts of humans and are implicated in numerous clinical infections, ranging from urinary tract infections to infective endocarditis, where they are responsible for between 5 and 15 percent of cases (52, 53, 54, 55, 56) . For our purposes, E. faecalis is a convenient model species because it rapidly evolves resistance to antibiotics in the laboratory (57, 58) , and fully sequenced reference genomes are available (59) .
By combining parallel experimental evolution of E. faecalis with high-throughput dose-response measurements, we provide collateral sensitivity and resistance profiles for 60 strains evolved to 15 different antibiotics, yielding a total of 900 mutant-drug combinations. We find that cross resistance and collateral sensitivity are pervasive in drug-resistant mutants, though patterns of collateral effects can vary significantly, even for mutants evolved to the same drug. Notably, however, the sensitivity profiles cluster into groups characterized by selecting drugs from similar drug classes, indicating the existence of large scale statistical structure in the collateral sensitivity profiles.
To exploit that structure, we develop a simple mathematical framework based on a Markov Decision Process (MDP) to identify optimal antibiotic policies that minimize resistance. These policies yield drug sequences that can be tuned to optimize either short-term or long-term evolutionary outcomes, and they codify the trade-offs between instantaneous drug efficacy and delayed evolutionary consequences. While clearly 50 of the testing drug relative to that of wild-type (V583) cells. While the color scale ranges from a 4x decrease to a 4x increase in IC 50 , it should be noted that both resistance to the selecting drug (diagonal blocks) and collateral effects can be significantly higher. Each column of the heat map represents a collateral sensitivity profile for one mutant. Right panel: enlarged first column from main panel. Mutants isolated from replicate populations evolved to daptomcyin exhibit diverse sensitivity profiles. While all mutants are resistant to the selecting drug (daptomycin), mutants may exhibit either sensitivity or resistance to other drugs. For example, the first and last replicates exhibit cross resistance to ceftriaxone (CRO), while replicate 2 exhibits collateral sensitivity and replicate 3 shows little effect.
FIG 1 Collateral effects are pervasive and vary across parallel evolution experiments in E. faecalis. A. E. faecalis strain V583 was exposed to increasing concentrations of a single antibiotic over an 8-day serial passage experiment with daily 200-fold dilutions (≈60 generations total; see Methods). The evolution was performed in quadruplicate for each drug and repeated for a total of 15 drugs (Table 2). After 8 days, a single mutant was isolated from each population. B. The half maximal inhibitory concentration (IC 50 ) for each of 15 drugs was estimated for all 60 mutants by nonlinear fitting of a dose response curve (relative OD) to a Hill-like function (Methods). C. Main panel: resistance (red) or sensitivity (blue) of each evolved mutant (horizontal axis; 15 drugs x 4 mutants per drug) to each drug (vertical axis) is quantified by the log 2 -transformed relative increase in the IC
too simple to capture evolution in realistic clinical scenarios, the model points to new conceptual strategies for mitigating resistance by balancing short-term growth inhibition with infrequent use of drugs intended to steer pathogen populations to a more vulnerable future state.
RESULTS

Collateral effects are pervasive and heterogeneous
To investigate collateral drug effects in E. faecalis, we exposed four independent populations of strain V583
to increasing concentrations of a single drug over 8 days (approximately 60 generations) using serial passage laboratory evolution ( Figure 1A , Methods). We repeated this laboratory evolution for a total of 15 antibiotics spanning a wide range of classes and mechanisms of action (Table 2) . Many, but not all, of these drugs are clinically relevant for the treatment of enterococcal infections. As a control, we also evolved 4 independent populations of the ancestral V583 strain to media (BHI) alone. After approximately 60 generations, we isolated a single colony (hereafter termed a "mutant") from each population and measured its response to all 15 drugs using replicate dose-response experiments ( Figure 1B) . To quantify resistance, we estimated the half maximal inhibitory concentration (IC 50 ) for each mutant-drug combination using non-linear least squares fitting to a Hill-like dose response function (Methods; see Figure S1 for examples Isolates exhibit variability in fitness costs and collateral profiles To investigate the potential impact of resistance mutations on fitness, we estimated the specific growth rate and the lag time in drug-free media for isolates selected from each of the 60 populations (4 populations per selecting drug). The growth costs exhibit significant variability, even across different populations selected by the same drug ( Figure 2 , similar to results in other species (49) . In some isolates-such as those selected by oxacillin (OXA) or nitrofurantoin (NIT)-growth rate and lag times are indistinguishable from those of the ancestral strains. On the other hand, isolates selected by CRO and FOF-selecting conditions that frequently result in collateral sensitivity-show dramatically reduced growth and an increased lag time, suggesting that the selected resistance determinants are associated with strong pleiotropic effects even in drug-free media.
Our results indicate that collateral profiles can vary significantly even when mutants are evolved in parallel to the same drug ( Figure 1C ). For example, all 4 mutants selected by daptomycin (DAP) exhibit high-level resistance to the selecting drug, but replicates 1 and 4 exhibit collateral resistance to CRO, while replicate 2 exhibits collateral sensitivity and replicate 3 shows little effect ( Figure 1C 
−1 , where µ is the maximum specific growth rate, λ is the lag time, and K is the carrying capacity. To reduce the number of free parameters, we fix K = 0. Figure 3A ).
Selection by LZD leads to higher CHL resistance than direct selection by CHL Surprisingly, we found that isolates selected by linezolid (LZD) developed higher resistance to chloramphenicol (CHL) than isolates selected directly by CHL ( Figure 3B ).
The isolates from LZD and from CHL exhibit similar growth and lag-time distributions in drug-free media (Figure 2 ), suggesting that this effect is not driven by fitness costs alone. To investigate further, we isolated LZD-selected mutants at days 2, 4, 6 and 8 of the laboratory evolution and measured the resistance of each to CHL. We find that early-stage (days 4-6) mutants exhibit low level CHL sensitivity just prior to a dramatic increase in cross resistance around day 8. These findings suggest LZD selection drives the population across a CHL fitness valley, ultimately leading to levels of resistance that exceed those observed by direct CHL selection ( Figure 3B , inset).
To further investigate the repeatability of this phenomenon, we exposed 32 additional populations to increasing LZD concentrations in parallel over 8 days. Using the four initial LZD mutants as a guide, we measured the CHL susceptibility of isolates from each population at day 5 ( Figure 3C , purple) and day 8 ( Figure 3C , blue). In addition, to account for potential heterogeneity in the original populations, we measured CHL susceptibility in three different (single colony) isolates from each of the original four populations selected in CHL ( Figure 3C , black Figure 3C ; specific isolates marked by black arrows). We did not observe mutations in rpsJ, L3 or 23SB in any strain. In addition, the four LZD-selected isolates showed no mutations in any of the sequenced genes on day 5 ( Figure 3D ). By contrast, all 4 of the LZD-selected strains contained at least 3 mutations in the 23S rRNA genes on day 8. Two of the CHL-selected isolates had mutations in L4 and one had a single mutation in the 23SC gene.
We observe a strong correlation between the level of CHL resistance and the total number of 23S rRNA mutations, similar to the dosing behavior previously observed for LZD (64) . This correlation suggests that the 23S mutations found in LZD-selected (and CHL-resistant) isolates from day 8-but missing in the CHL-sensitive isolates from day 5-may be responsible for the later-stage, high-level cross resistance to CHL. Elucidating the precise evolutionary dynamics underlying differential selection for these mutations in LZD and CHL remains an open question, though the early (day 5) CHL-sensitivity observed in LZD-selected isolates suggests it may be necessary to cross a fitness valley in CHL resistance in order to eventually achieve higher CHL resistance.
Whole-genome sequencing reveals known resistance determinants and mutations in genes previously linked with collateral sensitivity To investigate the genetic changes in drug-selected populations, we sequenced population samples from one evolved population per drug. In addition, we isolated and sequenced a single clone from each population. As controls, we sequenced two different isolates from the ancestral V583 stock as well as both single isolates and a population sample propagated in drug-free media. We then used breseq (65) , an established computational pipeline capable of mutant identification in both clonal and population samples (Methods). To minimize potential artifacts from sample preparation or analysis, we excluded from further analysis four populations where variants identified by clonal and population samples did not overlap. In addition, we limit our focus to those mutations estimated to occur with frequency greater than 30 percent in the population samples.
This analysis revealed a total of 29 mutations in the 11 populations (Table 1; note that the population selected in NIT contained no identifiable mutations). The control strain propagated in BHI contained no mutations relative to the ancestral strains. For 9 of the 11 selecting drugs, we identified mutations that likely confer resistance to the selecting drug. For example, we observed mutations in drug targets associated with protein synthesis inhibitors (rpsJ (66) , rpsE (67) ), fluoroquinolones (parC, gyrA (68)),
and RNA synthesis inhibitors (rpoB (68)). We also identified mutations in a sensor histidine kinases (69, 70) (EF_3290) in populations selected by cell-wall inhibitors and mutations in 23S rRNA genes in the LZD-selected population (64, 71) . Surprisingly, the DAP-selected population did not contain mutations in genes previously identified with DAP resistance (57, 58), though we observe a mutation in rpsJ in both the clonal and population sequences. While previous experiments have shown rpsJ not to confer DAP For example, previous work showed (in a different context) that pairwise interactions between simultaneously applied antibiotics can be used to cluster drugs into groups that interact monochromatically with one another; these groups correspond to known drug classes (76) , highlighting statistical structure in drug interaction networks that appear, on the surface, to be extremely heterogeneous. Recent work in bacteria has also shown that phenotypic profiles of mutants selected by drugs from the same class tend to cluster together in P. aeruginosa (38) and E. coli (77) .
Similarly, we asked whether collateral sensitivity profiles in E. faeaclis can be used to cluster resistant mutants into statistically similar classes. We first performed hierarchical clustering (Methods) on collateral profiles of 52 different mutants ( Figure 4 ,
x-axis; note that we excluded mutants selected by CHL and NIT, which did not achieve resistance of at least 2x to the selecting drug). Despite the heterogeneity in collateral profiles, they cluster into groups characterized-exclusively-by selecting drugs from the same drug classes before grouping mutants from any two different drug classes. A Markov decision process (MDP) model predicts optimal drug policies to constrain resistance Our results indicate that collateral sensitivity is pervasive, and while collateral sensitivity profiles are highly heterogeneous, clustering suggests the existence of statistical structure in the data. Nevertheless, because of the stochastic nature of the sensitivity profiles, it is not clear whether this information can be leveraged to design drug sequences that constrain evolution. It is important to note that our goal, at this stage, is not to design specific drug sequences that might be transferred directly to the clinic, but instead to evaluate-in a simple setting-the feasibility of slowing resistance in even the most optimized cases. Given that resistance to the selecting drugs is often larger in magnitude than collateral (off-diagonal) effects, it is not clear a priori that a feasible strategy exists that prevents the inevitable march to high-level resistance, even in a highly idealized setting.
To address this problem, we develop a simple mathematical model based on a Markov decision process (MDP) to predict optimal drug policies. MDP's are widely used in applied mathematics and finance and have a well-developed theoretical basis (78, 79, 80) . In a MDP, a system transitions stochastically between discrete states. At each time step, we must make a decision (called an "action"), and for each stateaction combination there is an associated instantaneous "reward" (or cost). The action influences not only the instantaneous reward, but also which state will occur next. The goal of the MDP is to develop a policy-a set of actions corresponding to each state-that will optimize some objective function (e.g. maximize some cumulative reward) over a given time period.
For our system, the state s t at time step t = 0, 1, 2, ... is defined by the resistance profile of the population, a vector that describes the resistance level to each available drug. At each time step, an action a t is chosen that determines the drug to be applied. The system-which is assumed to be Markovian-then transitions with probability P a (s t +1 |s t , a t ) to a new state s t i +1 , and the transition probabilities are estimated from evolutionary experiments (or any available data). The instantaneous reward function R a (s) is chosen to be the (negative of the) resistance to the currently applied drug; intuitively, it provides a measure of how well the current drug inhibits the current population. The optimal policy π * (s) is formally a mapping from each state to the optimal action; intuitively, it tells which drug should be applied for a given resistance profile.
The policy is chosen to maximize a cumulative reward function R c ≡ ∞ t =0 γ t R π (s t ) , where brackets indicate an expectation value conditioned on the initial state s 0 and the choice of policy π. The parameter γ (0 ≤ γ < 1) is a discount factor that determines the timescale for the optimization; γ ≈ 1 leads to a solution that performs optimally on long timescales, while γ ≈ 0 leads to solutions that maximize near-term success.
To apply the MDP framework to collateral sensitivity profiles, we must infer from our data a set of (stochastic) rules for transitioning between states (i.e. we must estimate P a (s t +1 |s t , a t )). While many choices are possible-and different rules may be useful to describing different evolutionary scenarios-here we consider a simple model where the resistance to each drug is increased/decreased additively according to the collateral effects measured for the selecting drug in question. Specifically, the state s t +1 following application of a drug at time t is given by s t +C , whereC is one of the four collateral profiles (see Figure 1 ) measured following selection by that drug. Because resistance/sensitivity is measured using log-scaled ratios of IC 50 's, these additive changes in the resistance profile correspond to multiplicative changes in the relative IC 50 for each drug. For instance, if one selection step increases the IC 50 by a factor of 3, then two consecutive selection steps would increase IC 50 by a factor of 9. This model assumes that selection by a given drug always produces changes in the resistance profile with the same statistical properties. For example, selection by DAP increases the resistance to DAP (with probability 1) while simultaneously either increasing resistance to AMP (with probability 1/4), decreasing resistance to AMP (with probability 1/4), or leaving resistance to AMP unchanged (probability 1/2). Repeated application of the same drug will steadily increase the population's resistance to that drug, but the process could potentially sensitize the population to other drugs. This model implicitly assumes sufficiently strong selection that, at each step, the state of the system is fully described by a single "effective" resistance profile (rather than, for example, an ensemble of profiles that would be required to model clonal interference).
While we focus here on this particular model, we stress that this MDP framework can be easily adopted to other scenarios by modifying P a (s t +1 |s t , a t ).
For numerical efficiency, we discretized both the state space (i.e. the resistance to each drug is restricted to a finite number of levels) as well as the measured collateral profiles (exposure to a drug leads to an increase/decrease of 0, 1, or 2 resistance levels; Figure 5A , Figure S3 ). In practice, this means that resistance will eventually saturate at a finite value if a single drug is applied repeatedly. In addition, we restrict our calculations to a representative subset of six drugs (DAP, AMP, FOF, TGC, LZD, RIF). The set includes inhibitors of cell wall, protein, or RNA synthesis, and five of the six drugs (excluding RIF) are clinically relevant for enterococcus infections. We note, however, that the results are qualitatively similar for different discretization schemes ( Figure S4 ) and for different drug choices (Figures S5-S7 ). 
Drug policies can be tuned to minimize resistance on different timescales
The optimal policy π * (s) is a high-dimensional mapping that is difficult to directly visualize. For intuition on the policy, we calculated the frequency with which each drug is prescribed as a function of resistance to each of the six individual drugs (Figures S8, S9 ; top panels). Not surprisingly, we found that when resistance to a particular drug is very low, that drug is often chosen as optimal. In addition, the specific frequency distributions vary significantly depending on γ, which sets the timescale of the optimization. For example, the long-term optimal policy (γ = 0.99) yields a frequency distribution that is approximately independent of the level of resistance to FOF ( Figure S8, upper right panel) . By contrast, the frequency distribution for a short-term policy (γ = 0.1) changes with FOF resistance; at low levels of resistance, FOF is frequently applied as the optimal drug, but it is essentially never applied once FOF resistance reaches a certain threshold ( Figure S9, upper right panel) . Both the shortand long-term optimal policies lead to aperiodic drug sequences, but the resulting resistance levels vary significantly ( Figures S8, S9 , bottom panels). These differences reflect a key distinction in the policies: short-term policies depend sensitively on the current resistance level and maximize efficacy (minimize resistance) at early times, while long-term policies may tolerate short-term performance failure in exchange for success on longer timescales.
Optimal policies outperform random cycling and rely on collateral sensitivity To compare the outcomes of different policies, we simulated the MDP and calculated the expected resistance level to the applied drug over time, R (t ) , from 1000 independent realizations ( Figure 5B ). All MDP policies perform significantly better than random drug cycling for the first 10-20 time steps and even lead to an initial decrease in resistance. The long-term policy (γ = 0.99, blue) is able to maintain low-level resistance indefinitely, while the short-term policy (γ = 0) eventually gives rise to high-level (almost saturating) resistance. Notably, if we repeat this calculation on an identical data set but with all collateral sensitivities set to 0, the level of resistance rapidly increases to its saturating value ( Figure 5B , light red line), indicating that collateral sensitivity is critical to the success of these policies. We note that the timescales used here are not necessarily reflective of a clinical situation, and instead our goal is to understand the performance of the optimization over a wide range of timescales.
Optimal policies highlight new strategy for minimizing resistance To understand the optimal policy dynamics, we calculated the time-dependent probability distributions P(Drug)-the probability of applying a particular drug-and P(Resist)-the probability of observing a given level of resistance to the applied drug-for the MDP following the long-term policy (γ = 0.99, Figure 5C-D) . We also calculated the (steady state) joint probability distribution characterizing the prescribed drugs at consecutive time steps ( Figure 5E ). The distributions reveal highly non-uniform behavior; after an initial transient period, RIF is applied most often, followed by FOF, while DAP is essentially never prescribed. Certain patterns also emerge between consecutively applied drugs; for example, FOF is frequently followed by RIF. Somewhat surprisingly, the distribution of resistance levels is highly bimodal, with the lowest possible resistance level occurring most often, followed by the highest possible level, then the second lowest level, and then the second highest level ( Figure 5D ). The policy achieves a low average level of resistance not by consistently maintaining some intermediate level of resistance to the applied drug, but instead by switching between highly-effective drugs and highly-ineffective drugs, with the latter occurring much less frequently. In words, rare periods of high resistance are the price of frequent periods of very low resistance. These qualitative trends occur for other drug choices (Figures S5-S7 ) and are relatively insensitive to the number of discretization levels chosen ( Figure S4) . The results suggest a new conceptual strategy for minimizing resistance: interspersing frequent steps of instantly effective drugs (low resistance)-which provide short-term inhibition of pathogen growth-with rare steps of relatively ineffective drugs (high resistance), which provide little short-term inhibition but shepherd the population to a more vulnerable future state.
Optimal policies maintain lower long-term resistance than collateral sensitivity cycles The resurgent interest in collateral sensitivity was sparked, in part, by innovative recent work that demonstrated the successful application of collateral sensitivity cycles, where each drug in a sequence promotes evolved sensitivity to the next drug (41) . To compare the performance of the MDP to that expected from collateral sensitivity cycles, we identified all collateral sensitivity cycles for the six drug network and calculated R (t ) for 100 time steps of each cycle. We then determined the "best" cycle of a given length-defined as the cycle with the lowest mean value of R (t ) over the last ten time steps-and compared the performance of those cycles to the shortand long-term MDP policies ( Figure 5F ). The MDP long-term optimal solution (γ = 0.99) maintains resistance at a lower average value than for all of the collateral sensitivity Optimized drug sequences improve growth inhibition and reduce adaptation rates in lab evolution experiments The MDP-based optimal policies perform well in stochastic simulations and highlight new strategies for potentially slowing resistance. However, the model contains a number of assumptions that lead to an oversimplified picture of the true evolutionary dynamics. As a result, it is not clear whether optimized drug sequences from this model will be effective in real, evolving pathogen populations.
To test the performance of MDP-based drug cycles, we designed a lab evolution experiment comparing inhibitory effects of different drug cycling protocols over 20 days. For experimental feasibility, we restrict our focus to a subset of four drugs (FOF, RIF, AMP, TGC) and reduced the length of each evolutionary time step from 8 days-as in the original collateral sensitivity experiment (Figure 1) -to 2 days. First, we experimentally measured the collateral sensitivity matrix for the four drug set following 2 days of lab evolution in eight replicate populations per drug ( Figure 6A ). We then calculated the optimal policy for two different values of γ (γ = 0.9, γ = 0.78), both corresponding to timescales commensurate with the planned experiment. In both cases, the steady state distribution of drug application P(Drug) calls for frequent use of TGC and relatively rare use of FOF, though the specific distribution depends on the particular choice of γ ( Figure 6B , top panel; see also Figure S10 ).
An exact application of the optimal policy requires measuring the full sensitivity profile at each step and using that profile, in accordance with the policy, to choose the next drug in the sequence. However, simulations suggest that choosing a predetermined drug cycle-that is, a cycle drawn from a particular realization of the stochas- (Figure 6B , bottom; see Figure S10 for γ = 0.78 example). To evaluate the efficacy of the MDP-derived cycle, we exposed a total of 60 replicate populations to one of 13 different drug cycle protocols (including the two MDP-derived cycles) over a 20-day serial passage lab evolution experiment. Every 40 hours, we measured the optical density of each population and then diluted each into fresh media containing the prescribed drug (added after a brief drug-free outgrowth phase, see Methods). Drug concentrations were chosen to be just above the MIC for ancestral populations-with MIC determined by complete absence of growth in ancestral strains after 24 hours under identical conditions-and the same concentration was applied at every time step calling for the associated drug. As a measure of drug efficacy, we defined the cumulative growth of a population at time t as the sum of the optical density measurements up to and including time t . Note that because drug-resistant populations often reach a steady-state carrying capacity-in our case, about OD=0.6-considerably faster than the 40-hour time window, cumulative growth is a conservative measure that underestimates differences in population size that would occur in exponentially-growing populations (for example, in a chemostat).
TGC-FOF-TGC
In addition to the two MDP-derived drug protocols, we also tested protocols calling for repeated application of each drug alone ( Figure 6C ), each of the six possible 2-drug cycles ( Figure 6D ), a four drug cycle consisting of repeated application of RIF- Figure 6E) , and a drug-free control (dashed lines, Figure 6C -E). In all cases, cumulative growth was normalized to the value of the drug-free control at the end of the 20-day experiment. To compare results from the model with experiment, we mapped each of the discrete resistance levels to an OD value, with the highest level of resistance corresponding to drug-free growth (OD≈ 0.6 each day) and the lowest resistance level corresponding to no growth (OD=0); see Figures S11, S12. We found experimentally that cycles involving sequential application of drugs with (on average) mutual collateral sensitivity-for example, cycles of RIF-FOF or RIF-AMP (see ( Figure 6A )-are among the best-performing two-drug cycles, as predicted by previous studies (41) . However, the MDP-derived protocols led to a significant reduction in cumulative growth, outperforming every other protocol, often by significant margins ( Figure 6 ; Figure S10 ). In addition to cumulative growth, we characterized each trajectory by calculating the adaptation rate, which is defined as the average rate of increase of instantaneous growth over time (i.e. the slope of the best-fit regression line for instantaneous growth vs time over days 2-20, Figures S13-S14). Adaptation rate, which is essentially an estimate of the average convexity of the cumulative growth curves, provides no information on the magnitude of the growth at each step, but instead measures how rapidly that growth is increasing over time (starting with the first measurement after day 2). In addition to reducing cumulative growth, the MDP-derived sequences led to lower rates of adaptation than nearly every other protocol ( Figure 6F ; Figure S10F ). A notable exception is the TGC-AMP cycle, which exhibits a (small) negative adaptation rate, reflecting that fact that growth at day 2 has already achieved relatively high levels-roughly 60 percent of drug-free growth-suggesting that adaptation largely occurs in that first period but is nearly absent after that. to CHL than direct selection by CHL. While choramphenicol is rarely used clinically, the result illustrates that 1) collateral effects can be highly dynamic, and 2) indirect selection may drive a population across a fitness valley to an otherwise inaccessible fitness peak.
FOF-TGC-AMP ((
DISCUSSION
Our findings also point to global trends in collateral sensitivity profiles. For example, we found that the repeatability of collateral effects is sensitive to the drug used for selection, meaning that some drugs may be better than others for establishing robust antibiotic cycling profiles. On the other hand, despite the apparent unpredictability of collateral effects at the level of individual mutants, the sensitivity profiles for mutants selected by drugs from known classes tend to cluster into statistically similar groups.
As proof-of-principle, we show how these profiles can be incorporated into a simple mathematical framework that optimizes drug protocols while accounting for effects of both stochasticity and different time horizons. Within this framework, drug policies can be tuned to optimize either short-term or long-term evolutionary outcomes. The ability to systematically tune these timescales may eventually be useful in designing drug protocols that interpolate between short-term, patient-centric outcomes and long-term, hospital-level optimization.
Our results complement recent studies on collateral sensitivity and also raise a number of new questions for future work. Much of the previous work on collateral networks in bacteria has focused on gram-negative bacteria and highlighted the role of aminoglycosides in collateral sensitivity (41, 36) . Many gram-positive bacteria, including enterococci, are intrinsically resistant to aminoglycosides (82), and we therefore included only one (SPT) in our study. In that case, however, we did observe collateral sensitivity to cell wall inhibitors (AMP and FOF) in SPT-selected populations, consistent with findings in other species (41, 36) , though it is not clear from our results whether aminoglycoside resistance would be associated with more widespread collateral sensitivity in E. faecalis. Recent work demonstrates that collateral profiles may be largely conserved across a wide range of E. coli isolates (77), offering hope that large scale analysis of clinical isolates may soon identify similar patterns in enterococci.
Multiple studies have shown that collateral profiles are heterogeneous (49, 50) , and optimization will therefore require incorporation of stochastic effects such as likelihood scores (51) . These likelihood scores could potentially inform transition probabilities in our MDP approach, leading to specific predictions for optimal drug sequences based on known fitness landscapes. While we have quantified the variability in evolved populations in several ways (e.g. variability scores, interprofile distance, population sequencing), we cannot definitely comment on the source of that variability; it could arise, for example, from different fixation events in independent populations or, alternatively, from clonal interference and random sampling in isolating individual clones. Indeed, population sequencing does suggest some measure of heterogeneity, even when we limit our analysis to mutations occurring at greater than 30 percent. In any event, our results point to a rich collection of possible collateral profiles, meaning that successful approaches for limiting resistance will likely require incorporation of variability and heterogeneity.
Several previous studies have indicated that cycles involving mutually collaterally sensitive drugs may be chosen to minimize the evolution of resistance (41, 42) .
In the context of our MDP model, these cycles fall somewhere between the shorttime-horizon optimization and the long-term optimal strategy, and in some cases, the collateral sensitivity cycling can lead to considerable slowing of resistance. However, our results indicate that the MDP optimizations on longer time-horizons lead to systematically lower resistance, a consequence of intermixing (locally) sub-optimal steps where the drug is instantaneously less effective but shepherds the population to a more vulnerable evolutionary state. We also find experimentally that mutual collateral sensitivity cycles with two drugs do generally outperform most other twodrug and single-drug protocols-as predicted by previous studies-but they generally underperform the MDP-based sequences.
It is important to keep in mind several limitations of our work. Designing effective drug protocols for clinical use is an extremely challenging and multi-scale problem. Our approach was not to develop a detailed, clinically accurate model, but instead to focus on a simpler question: optimizing drug cycles in single-species host-free populations.
Even in this idealized scenario, which corresponds most closely to in vitro lab experiments, slowing resistance is a difficult and poorly understood problem (despite much recent progress). Our results are promising because they show systematic optimization is indeed possible given the measured collateral sensitivity profiles.
We have chosen to focus on a simple evolutionary scenario where collateral effects accumulate over time based on the history of drug exposure. By using a simple model that can be analyzed in detail, our goal was to identify new conceptual strategies-and with them, experimentally testable predictions-for exploiting correlations in phenotypic resistance profiles. While we've focused on an extremely simple model, the MDP framework can be readily extended to account for different evolutionary scenarios and to incorporate more complex clinically-inspired considerations. For example, it would be straightforward to include fitness costs associated with different resistance profiles;
in turn, the model might be extended to allow for drug-free periods ("drug holidays"), which potentially exploit these fitness costs to minimize resistance (50) . In addition, the current model inherently assumes that the dominant collateral effects are independent of the genetic background. In fact, collateral sensitivity profiles in cancer have been previously shown to be time-dependent (83, 50) , epistasis certainly occurs (49, 84) , and population heterogeneity could limit efficacy of this strategy under some conditions (85) . Unfortunately, the frequency and relative impact of these confounding effects are difficult to gauge. However, the relative success of the MDP-inspired sequences in lab evolution experiments underscores the potential of the approach. In particular, our findings offer hope that strategies combining frequent use of highly effective drugs with rare periods of "evolutionary steering" by less effective drugs may be promising even when the detailed assumptions of the model do not strictly hold.
Our future work will focus on experimentally characterizing dynamic properties of collateral effects and expanding the MDP approach to account for time-varying sensitivity profiles and epistasis. It may also be interesting to investigate collateral effects in microbial biofilms, where antibiotics can have counterintuitive effects even on evolutionarily short timescales (86) . On longer timescales, elegant experimental approaches to biofilm evolution have revealed that spatial structure can give rise to rich evolutionary dynamics (87, 88) and potentially, but not necessarily, divergent results for biofilm and planktonic populations (89) Finally, our results raise questions about the potential molecular and genetic mechanisms underlying the observed collateral effects. The phenotypic clustering analysis presented here may point to shared mechanistic explanations for sensitivity profiles selected by similar drugs, and the full genome sequencing identifies candidate genes associated with increased resistance. However, fully elucidating the detailed genetic underpinnings of collateral sensitivity remains an ongoing challenge for future work. At the same time, because the MDP framework depends only on phenotypic measurements, it may allow for systematic optimization of drug cycling policies even when molecular mechanisms are not fully known. Table 2 . Each antibiotic was prepared from powder stock and stored at -20°C with the exception of ampicillin, which was stored at -80°C. Evolution and IC 50 measurements were conducted in BHI medium alone with the exception of DAP, which requires an addition of 50 mM calcium for antimicrobial activity.
Laboratory Evolution Experiments Evolution experiments to each antibiotic
were performed in quadruplicate. Evolutions were performed using 1 mL BHI medium in 96-well plates with maximum volume 2 mL. Each day, populations were grown in at least three different antibiotic concentrations spanning both sub-and super-MIC doses.
After 16-20 hours of incubation at 37°C, the well with the highest drug concentration that contained visual growth was propagated into 2 higher concentrations (typically a factor 2x and 4x increase in drug concentration) and 1 lower concentration to maintain a living mutant lineage (always half the concentration that most recently produced growth). A 1/200 dilution was used to inoculate the next day's evolution plate, and the process was repeated for a total of 8 days of selection. On the final day of evolution all strains were stocked in 30 percent glycerol. Strains were then plated on a pure BHI plate and a single colony was selected for IC 50 determination. In the case of LZD mutants, days 2, 4, and 6 were also stocked for further testing. After 20 hours of growth the optical density at 600 nm (OD600) was measured using an Enspire Multimodal Plate Reader (Perkin Elmer) with an automated 20-plate stacker assembly. This process was repeated for all 60 mutants as well as the wild-type, which was measured in replicates of 8.
Measuring Drug Resistance and Sensitivity
The optical density (OD600) measurements for each drug concentration were normalized by the OD600 in the absence of drug. To quantify drug resistance, the resulting dose response curve was fit to a Hill-like function f (x ) = (1 + (x /K ) h ) −1 using nonlinear least squares fitting, where K is the half-maximal inhibitory concentration (I C 50 ) and h is a Hill coefficient describing the steepness of the dose-response relationship. A mutant strain was defined to be collaterally sensitive if its IC 50 had decreased by more than 3σ W T relative to the ancestral strain (σ W T is defined as the uncertainty-standard error across replicates-of the IC 50 measured in the ancestral strain). Similarly, an increase in IC 50 by more than 3σ W T relative to the ancestral strain corresponds to cross-resistance.
Hierarchical clustering Hierarchical clustering was performed in Matlab using, as input, the collateral profilesC for each mutant. The distance between each pair of mutants was calculated using a correlation metric (Matlab function pdist with parameter 'correlation'), and the linkage criteria was chosen to be the mean average linkage clustering.
Markov decision process (MDP) model
The MDP model consists of a finite set of states (S ), a finite set of actions (A), a conditional probability (P a (s |s, a)) describing (action-dependent) Markovian transitions between these states, and an instantaneous reward function (R a (s)) associated with each state and action combination. The state of the system s ∈ S is an n d -dimensional vector, with n d the number of drugs and each component s i ∈ {r mi n , r mi n + 1, ..., r max } indicating the level of resistance to drug i . The action a ∈ A ≡ {1, 2, ..., n d } is the choice of drug at the current step, and we take the reward function R a (s) to be the (negative of the) resistance level to the currently applied drug (i.e. the a-th component of s). The goal of the MDP is to identify a policy π(s), which is a mapping from S to A that specifies an optimal action for each state. The policy is chosen to maximize a cumulative reward function R c = ∞ t =0 γ t R π (s t ) , where t is the time step, s t is the state of the system at time t , R π (s t ) is a random variable describing the instantaneous reward assuming that the actions are chosen according to policy π, and brackets indicate an expectation value. The parameter γ (0 ≤ γ < 1) is a discount factor that determines the relative importance of instantaneous vs long-term optimization. In words, we seek an optimal policy-which associates the resistance profile of a given population to an optimal drug choice-that minimizes the cumulative expected resistance to the applied drug.
The MDP problem was solved using value iteration, a standard dynamic programming algorithm for MDP models. Briefly, the optimization was performed by first computing the optimal value function V (s), which associates to each state s the expected reward obtained by following a particular policy and starting in that state.
Following the well-established value iteration algorithm (80, 78, 79) , we iterate according to V i +1 (s) = max {a } (R a (s) + γ s P (s |s, a)V i (s )). Given the optimal value function, the optimal policy is then given by the action that minimizes the optimal value function at the next time step.
Once the optimal policy π = π * is found, the system is reduced to a simple Markov chain with transition matrix T π * = P π * (s) (s |s, π * (s)), where the subscript π * means that the decision in each state is determined by the policy π * (i.e. that a = π * (s) for a system in state s). Explicitly, the Markov chain dynamics are given by P t +1 (s) = T π * P t (s), with P t (s) the probability to be in state s at time step t . All quantities of interest-including P(Drug), P(Resist) (see Figure 5) , and R (t ) -can be calculated directly from P t (s). For example, R (t ) = s ∈S P t (s)R π * (s), with R π * (s) the instantaneous reward for a system in state s under optimal policy π * . 
Experiments to evaluate different drug sequence protocols
